Hemostasis Analyzers Market is speculated to be worth US$ 6,490.24 million by 2028, says The Insight Partners

Hemostasis Analyzers Market is speculated to be worth US$ 6,490.24 million by 2028, says The Insight Partners

According to The Insight Partners’ research, the global hemostasis analyzers market was valued at US$ 3,440.66 million in 2021 and is expected to hit US$ 6,490.24 million by 2028, recording an annual growth rate of 9.5% from 2021 to 2028. The high prevalence of cardiovascular diseases and rising geriatric population are the critical elements aiding the market expansion.

Cardiovascular diseases (CVDs), such as cerebrovascular disease, coronary heart disease, and rheumatic heart disease, are among the leading causes of morbidity and mortality across the world. Unhealthy lifestyle habits such as tobacco consumption, poor diet, and physical inactivity also worsen the conditions as they are susceptible to increased risk of heart attacks and strokes. Other hazardous factors causing CVDs are high blood pressure, diabetes, and cholesterol levels. Hemostasis analyzers provide a quick and easy measurement of blood platelet levels. A coagulation test detects and prevents blood clots that could cause a heart attack.

Download Exclusive Sample PDF Copy of market Study @ https://www.theinsightpartners.com/sample/TIPRE00016709/

Leading players profiled in the global hemostasis analyzers market report are Siemens Healthineers AG; Abbott; Sysmex Corporation; Nihon Kohden Corporation; Thermo Fisher Scientific Inc; Hoffmann-la Roche Ltd; Instrumentation Laboratory Company; Helena Laboratories Corporation; Diagnostica Stago, Inc; and International Technidyne Corporation.

• In November 2016, Siemens Healthineers introduced a fully automated high-volume coagulation analyzer designed to streamline and unify hemostasis testing. In August 2021, the company launched Sysmex CN-3000 and CN-6000 hemostasis systems for mid and high-volume coagulation testing.
• In June 2017, Abbott introduced Sekisui CP3000 coagulation system, a fully automated analyzer that tests bleeding and clotting function in blood in European, Middle-East, and Asia Pacific markets.
• In January 2012, Hoffmann-la Roche Ltd entered into a strategic alliance with Technoclone, a reagent specialist in thrombosis and cardiovascular diagnostics based in Vienna, Austria.

Older people are prone to heart diseases due to weak immunity and other health problems. With the growing age, their systolic blood pressure also increases, leading to cardiovascular disorders. According to the Global Ageing 2019 survey, the number of people aged 65 years or above was 703 million in 2019. The elderly population is vulnerable to atypical presentations, comorbid conditions, and unfavorable outcomes. Increasing CVDs among older people demands hemostasis analysis which, in turn, bolsters the global hemostasis analyzers market.

On the other hand, the high cost of fully automated hemostasis analyzers hinders the growth of global hemostasis analyzers market.

According to product, the market is split into laboratory analyzers and point-of-care testing systems. The former held 61.77% market share in 2021 with a revenue total of US$ 2,125.29 million. It is estimated to generate US$ 3,973.36 million by 2028, expanding at 9.4% CAGR during 2021–2028.

Based on test, the hemostasis analyzers market domain is segmented into activated partial thromboplastin time, d-dimer test, fibrinogen test, prothrombin time (PT) test, and others. The d-dimer test segment occupied 28.78% share of the business in 2021. It was assessed at US$ 990.15 million in 2021 and is speculated to garner US$ 1,825.75 million by 2028, surging at 9.1% CAGR during the forecast period.

In terms of end user, the global hemostasis analyzers market is fragmented into hospitals/clinics, independent diagnostic laboratories, home care settings, and others. With 37.73% market share, the hospitals/clinics segment dominated the business in 2021. It amassed US$ 1,298.27 million in 2021 and is slated to accrue US$ 2,429.00 million by 2028, featuring a CAGR of 9.4% throughout the forecast period.

Our regional analysis states that North America captured 37.60% market share in 2021. It was evaluated at US$ 1,293.76 million in 2021 and is likely to reach US$ 2,462.45 million by 2028, exhibiting a CAGR of 9.6% over the forecast period. The market in Asia Pacific was assessed at US$ 736.69 million in 2021 and is forecasted to be worth US$ 1,424.59 million by 2028.

Place a Purchase Order to Buy a Complete Copy of this Report @ https://www.theinsightpartners.com/buy/TIPRE00016709/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: [email protected]

Phone: +1-646-491-9876

Published Wed, 17 Aug 2022 23:54:58 -0500